Dienogest
- Generic Name
- Dienogest
- Brand Names
- Natazia, Visanne
- Drug Type
- Small Molecule
- Chemical Formula
- C20H25NO2
- CAS Number
- 65928-58-7
- Unique Ingredient Identifier
- 46M3EV8HHE
- Background
Dienogest is an orally-active semisynthetic progestogen which also possesses the properties of 17α-hydroxyprogesterone. It is a derivative of 19-nortestosterone and has antiandrogenic properties. It is primarily used as a contraceptive in combination with ethinylestradiol, or in other combination form pills approved in United States and Europe however it is not available in the US by itself. In Europe, Australia, Malaysia, Singapore and Japan, dienogest single therapy is an approved treatment for endometriosis to alleviate painful symptoms of endometriosis and reduce endometriotic lesions . Dienogest is commonly marketed as Visanne, Natazia and Qlaira.
- Indication
Indicated for use as the treatment of endometriosis alone and as a contraceptive in combination with ethinylestradiol.
- Associated Conditions
- Hypermenorrhea, Pain
- Associated Therapies
- Contraception, Oral Contraceptives
Comparing the Use of Dienogest and Combined Oral Contraceptive Pills (Microgynon) to Reduce the Risk of Recurrence of Endometriotic Cyst After Conservative Surgery
- First Posted Date
- 2015-03-11
- Last Posted Date
- 2015-04-29
- Lead Sponsor
- The University of Hong Kong
- Target Recruit Count
- 144
- Registration Number
- NCT02385448
- Locations
- 🇭🇰
Queen Mary Hospital, Hong Kong, Hong Kong
Synthetic vs Natural Estrogen in Combined Oral Contraception
- Conditions
- Contraception
- Interventions
- First Posted Date
- 2015-02-02
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Helsinki University Central Hospital
- Target Recruit Count
- 59
- Registration Number
- NCT02352090
- Locations
- 🇫🇮
Helsinki University Central Hospital, Kätilöopisto Maternity Hospital, Helsinki, Finland
🇫🇮Oulu University Hospital, Department of Gynecology and Obstetrics, Oulu, Finland
Phase 3 Study of Dienogest for the Treatment of Endometriosis in Chinese Patients
- Conditions
- Endometriosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2013-04-02
- Last Posted Date
- 2015-11-25
- Lead Sponsor
- Bayer
- Target Recruit Count
- 250
- Registration Number
- NCT01822080
Regulatory Post Marketing Surveillance Study in Korea
- First Posted Date
- 2013-02-11
- Last Posted Date
- 2018-08-02
- Lead Sponsor
- Bayer
- Target Recruit Count
- 3223
- Registration Number
- NCT01788722
Study of the Efficacy of Dienogest in the Treatment of Uterine Leiomyomas When Compared to Desogestrel and Goserelin
- Conditions
- Uterine Leiomyoma
- Interventions
- First Posted Date
- 2012-11-30
- Last Posted Date
- 2020-08-13
- Lead Sponsor
- University of Sao Paulo
- Target Recruit Count
- 14
- Registration Number
- NCT01738724
Comparative Study of BAY86-5300 With an Extended Flexible Regimen for Endometriosis
- Conditions
- Endometriosis
- Interventions
- First Posted Date
- 2012-10-02
- Last Posted Date
- 2016-02-18
- Lead Sponsor
- Bayer
- Target Recruit Count
- 312
- Registration Number
- NCT01697111
Daily Practice Treatment and Influence of Visanne on the Patient Assessment of Quality of Life
- First Posted Date
- 2012-05-10
- Last Posted Date
- 2015-07-10
- Lead Sponsor
- Bayer
- Target Recruit Count
- 3006
- Registration Number
- NCT01595724
Visanne Study to Assess Safety in Adolescents
- First Posted Date
- 2011-01-26
- Last Posted Date
- 2015-08-13
- Lead Sponsor
- Bayer
- Target Recruit Count
- 111
- Registration Number
- NCT01283724
Pharmacodynamic Characterization of Dienogest
- Conditions
- Pharmacodynamics
- Interventions
- First Posted Date
- 2008-09-18
- Last Posted Date
- 2015-01-27
- Lead Sponsor
- Bayer
- Target Recruit Count
- 102
- Registration Number
- NCT00754871
Safety and Efficacy of SH T00660AA in Treatment of Endometriosis
- First Posted Date
- 2005-09-23
- Last Posted Date
- 2014-01-09
- Lead Sponsor
- Bayer
- Target Recruit Count
- 168
- Registration Number
- NCT00225186
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.